SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Nicholls J.) ;lar1:(liu)"

Sökning: WFRF:(Nicholls J.) > Linköpings universitet

  • Resultat 1-10 av 17
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Agirre, Jon, et al. (författare)
  • The CCP4 suite: integrative software for macromolecular crystallography
  • 2023
  • Ingår i: Acta Crystallographica Section D. - : INT UNION CRYSTALLOGRAPHY. - 2059-7983. ; 79, s. 449-461
  • Tidskriftsartikel (refereegranskat)abstract
    • The Collaborative Computational Project No. 4 (CCP4) is a UK-led international collective with a mission to develop, test, distribute and promote software for macromolecular crystallography. The CCP4 suite is a multiplatform collection of programs brought together by familiar execution routines, a set of common libraries and graphical interfaces. The CCP4 suite has experienced several considerable changes since its last reference article, involving new infrastructure, original programs and graphical interfaces. This article, which is intended as a general literature citation for the use of the CCP4 software suite in structure determination, will guide the reader through such transformations, offering a general overview of the new features and outlining future developments. As such, it aims to highlight the individual programs that comprise the suite and to provide the latest references to them for perusal by crystallographers around the world.
  •  
2.
  • Cruchley, S., et al. (författare)
  • Cautionary note on use of focused ion beam sectioning as technique for characterising oxidation damage in Ni based superalloys
  • 2014
  • Ingår i: Materials at High Temperature. - : Science Reviews 2000 Ltd.. - 0960-3409 .- 1878-6413. ; 31:1, s. 27-33
  • Tidskriftsartikel (refereegranskat)abstract
    • Previous observations on Ni based superalloys, obtained through the use of focused ion beam (FIB) sample preparation and imaging, have reported the presence of subsurface voids after oxidation. In this present study, oxidised specimens of the Ni based superalloy, RR1000, were subjected to conventional sample preparation as well as both dual and single beam FIB preparation, with the aim of re-examining the previous observations of subsurface void formation. It is clear from FIB preparations that features previously interpreted as networks of voids have been demonstrated to be internal oxides by varying the sample tilt angles and imaging signal using either secondary electrons (SEs) or secondary ions (SIs). Conventional preparation methods illustrate the presence of subsurface alumina intrusions and the absence of voids, supporting previous evidence. The positive identification of voids and oxides by FIB can be complex and prone to misinterpretation and thus, the use of several imaging conditions and tilt angles must be used, along with conventional preparation methods, to confirm or refute the presence of voids underneath oxides.
  •  
3.
  • Pitts, Reynaria, et al. (författare)
  • Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure
  • 2017
  • Ingår i: Journal of the American Heart Association. - : WILEY-BLACKWELL. - 2047-9980. ; 6:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Background- Aldosterone may have adverse effects in the myocardium and vasculature. Treatment with an aldosterone antagonist reduces cardiovascular risk in patients with acute myocardial infarction complicated by heart failure (HF) and left ventricular systolic dysfunction. However, most patients with acute coronary syndrome do not have advanced HF. Among such patients, it is unknown whether aldosterone predicts cardiovascular risk. Methods and Results- To address this question, we examined data from the dal-OUTCOMES trial that compared the cholesteryl ester transfer protein inhibitor dalcetrapib with placebo, beginning 4 to 12 weeks after an index acute coronary syndrome. Patients with New York Heart Association class II (with LVEF amp;lt; 40%), III, or IV HF were excluded. Aldosterone was measured at randomization in 4073 patients. The primary outcome was a composite of coronary heart disease death, nonfatal myocardial infarction, stroke, hospitalization for unstable angina, or resuscitated cardiac arrest. Hospitalization for HF was a secondary endpoint. Over a median follow-up of 37 months, the primary outcome occurred in 366 patients (9.0%), and hospitalization for HF occurred in 72 patients (1.8%). There was no association between aldosterone and either the time to first occurrence of a primary outcome (hazard ratio for doubling of aldosterone 0.92, 95% confidence interval 0.78-1.09, P=0.34) or hospitalization for HF (hazard ratio 1.38, 95% CI 0.96-1.99, P=0.08) in Cox regression models adjusted for covariates. Conclusions- In patients with recent acute coronary syndrome but without advanced HF, aldosterone does not predict major cardiovascular events.
  •  
4.
  • Schwartz, Gregory G., et al. (författare)
  • Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome Analysis of the dal-Outcomes Randomized Clinical Trial
  • 2018
  • Ingår i: JAMA cardiology. - : AMER MEDICAL ASSOC. - 2380-6583 .- 2380-6591. ; 3:2, s. 164-168
  • Tidskriftsartikel (refereegranskat)abstract
    • IMPORTANCE It is uncertain whether lipoprotein(a) [Lp(a)], which is associated with incident cardiovascular disease, is an independent risk factor for recurrent cardiovascular events after acute coronary syndrome (ACS). OBJECTIVE To determine the association of Lp(a) concentration measured after ACS with the subsequent risk of ischemic cardiovascular events. DESIGN, SETTING, AND PARTICIPANTS This nested case-cohort analysis was performed as an ad hoc analysis of the dal-Outcomes randomized clinical trial. This trial compared dalcetrapib, the cholesteryl ester transfer protein inhibitor, with placebo in patients with recent ACS and was performed between April 2008 and September 2012 at 935 sites in 27 countries. There were 969 case patients who experienced a primary cardiovascular outcome, and there were 3170 control patients who were event free at the time of a case event and had the same type of index ACS (unstable angina ormyocardial infarction) as that of the respective case patients. Concentration of Lp(a) was measured by immunoturbidimetric assay. Data analysis for this present study was conducted from June 8, 2016, to April 21, 2017. INTERVENTIONS Patients were randomly assigned to receive treatment with dalcetrapib, 600 mg daily, or matching placebo, beginning 4 to 12 weeks after ACS. MAIN OUTCOMES AND MEASURES Death due to coronary heart disease, a major nonfatal coronary event (myocardial infarction, hospitalization for unstable angina, or resuscitated cardiac arrest), or fatal or nonfatal ischemic stroke. RESULTS The mean (SD) age was 63 (10) years for the 969 case patients and 60 (9) years for the 3170 control patients, and both cohorts were composed of predominantly male (770 case patients [79%] and 2558 control patients [81%]; P = .40) and white patients (858 case patients [89%] and 2825 control patients [89%]; P = .62). At baseline, the median (interquartile range) Lp(a) level was 12.3 (4.7-50.9) mg/dL. There was broad application of evidence-based secondary prevention strategies after ACS, including use of statins in 4030 patients (97%). The cumulative distribution of baseline Lp(a) levels did not differ between cases and controls at P = .16. Case-cohort regression analysis showed no association of baseline Lp(a) level with risk of cardiovascular events. For a doubling of Lp(a) concentration, the hazard ratio (case to control) was 1.01 (95% CI, 0.96-1.06; P = .66) after adjustment for 16 baseline variables, including assigned study treatment. CONCLUSIONS AND RELEVANCE For patients with recent ACS who are treated with statins, Lp(a) concentration was not associated with adverse cardiovascular outcomes. These findings call into question whether treatment specifically targeted to reduce Lp(a) levels would thereby lower the risk for ischemic cardiovascular events after ACS.
  •  
5.
  • Schwartz, Gregory G., et al. (författare)
  • Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease
  • 2020
  • Ingår i: Diabetes Care. - : AMER DIABETES ASSOC. - 0149-5992 .- 1935-5548. ; 43:5, s. 1077-1084
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE Incident type 2 diabetes is common among patients with recent acute coronary syndrome and is associated with an adverse prognosis. Some data suggest that cholesteryl ester transfer protein (CETP) inhibitors reduce incident type 2 diabetes. We compared the effect of treatment with the CETP inhibitor dalcetrapib or placebo on incident diabetes in patients with recent acute coronary syndrome. RESEARCH DESIGN AND METHODS In the dal-OUTCOMES trial, 15,871 patients were randomly assigned to treatment with dalcetrapib 600 mg daily or placebo, beginning 4-12 weeks after an acute coronary syndrome. Absence of diabetes at baseline was based on medical history, no use of antihyperglycemic medication, and hemoglobin A(1c) and serum glucose levels below diagnostic thresholds. Among these patients, incident diabetes after randomization was defined by any diabetes-related adverse event, new use of antihyperglycemic medication, hemoglobin A(1c) >= 6.5%, or a combination of at least two measurements of serum glucose >= 7.0 mmol/L (fasting) or >= 11.1 mmol/L (random). RESULTS At baseline, 10,645 patients (67% of the trial cohort) did not have diabetes. During a median follow-up of 30 months, incident diabetes was identified in 403 of 5,326 patients (7.6%) assigned to dalcetrapib and in 516 of 5,319 (9.7%) assigned to placebo, corresponding to absolute risk reduction of 2.1%, hazard ratio of 0.77 (95% CI 0.68-0.88; P < 0.001), and a need to treat 40 patients for 3 years to prevent 1 incident case of diabetes. Considering only those with prediabetes at baseline, the number needed to treat for 3 years to prevent 1 incident case of diabetes was 25. Dalcetrapib also decreased the number of patients who progressed from normoglycemia to prediabetes and increased the number who regressed from diabetes to no diabetes. CONCLUSIONS In patients with a recent acute coronary syndrome, incident diabetes is common and is reduced substantially by treatment with dalcetrapib.
  •  
6.
  • Schwartz, Gregory G, et al. (författare)
  • Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
  • 2012
  • Ingår i: New England Journal of Medicine. - : Massachusetts Medical Society. - 0028-4793 .- 1533-4406. ; 367:22, s. 2089-2099
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND less thanbrgreater than less thanbrgreater thanIn observational analyses, higher levels of high-density lipoprotein (HDL) cholesterol have been associated with a lower risk of coronary heart disease events. However, whether raising HDL cholesterol levels therapeutically reduces cardiovascular risk remains uncertain. Inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels and might therefore improve cardiovascular outcomes. less thanbrgreater than less thanbrgreater thanMETHODS less thanbrgreater than less thanbrgreater thanWe randomly assigned 15,871 patients who had had a recent acute coronary syndrome to receive the CETP inhibitor dalcetrapib, at a dose of 600 mg daily, or placebo, in addition to the best available evidence-based care. The primary efficacy end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, unstable angina, or cardiac arrest with resuscitation. less thanbrgreater than less thanbrgreater thanRESULTS less thanbrgreater than less thanbrgreater thanAt the time of randomization, the mean HDL cholesterol level was 42 mg per deciliter (1.1 mmol per liter), and the mean low-density lipoprotein (LDL) cholesterol level was 76 mg per deciliter (2.0 mmol per liter). Over the course of the trial, HDL cholesterol levels increased from baseline by 4 to 11% in the placebo group and by 31 to 40% in the dalcetrapib group. Dalcetrapib had a minimal effect on LDL cholesterol levels. Patients were followed for a median of 31 months. At a prespecified interim analysis that included 1135 primary end-point events (71% of the projected total number), the independent data and safety monitoring board recommended termination of the trial for futility. As compared with placebo, dalcetrapib did not alter the risk of the primary end point (cumulative event rate, 8.0% and 8.3%, respectively; hazard ratio with dalcetrapib, 1.04; 95% confidence interval, 0.93 to 1.16; P = 0.52) and did not have a significant effect on any component of the primary end point or total mortality. The median C-reactive protein level was 0.2 mg per liter higher and the mean systolic blood pressure was 0.6 mm Hg higher with dalcetrapib as compared with placebo (Pandlt;0.001 for both comparisons). less thanbrgreater than less thanbrgreater thanCONCLUSIONS less thanbrgreater than less thanbrgreater thanIn patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events. (Funded by F. Hoffmann-La Roche; dal-OUTCOMES ClinicalTrials.gov number, NCT00658515.)
  •  
7.
  • Brown, Sally, et al. (författare)
  • Shifting perspectives on coastal impacts and adaptation
  • 2014
  • Ingår i: Nature Climate Change. - : Nature Publishing Group. - 1758-678X .- 1758-6798. ; 4:9, s. 752-755
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
    • The Intergovernmental Panel on Climate Change reports reflect evolving attitudes in adapting to sea-level rise by taking a systems approach and recognizing that multiple responses exist to achieve a less hazardous coast.
  •  
8.
  • Hinkel, Jochen, et al. (författare)
  • A global analysis of erosion of sandy beaches and sea-level rise: An application of DIVA
  • 2013
  • Ingår i: Global and Planetary Change. - : Elsevier. - 0921-8181 .- 1872-6364. ; 111, s. 150-158
  • Tidskriftsartikel (refereegranskat)abstract
    • This paper presents a first assessment of the global effects of climate-induced sea-level rise on the erosion of sandy beaches, and its consequent impacts in the form of land loss and forced migration of people. We consider direct erosion on open sandy coasts and indirect erosion near selected tidal inlets and estuaries, using six global mean sea-level scenarios (in the range of 0.2-0.8 m) and six SRES socio-economic development scenarios for the 21st century. Impacts are assessed both without and with adaptation in the form of shore and beach nourishment, based on cost-benefit analysis that includes the benefits of maintaining sandy beaches for tourism. Without nourishment, global land loss would amount to about 6000-17,000 km(2) during the 21st century, leading to 1.6-5.3 million people being forced to migrate and migration costs of US$ 300-1000 billion (not discounted). Optimal beach and shore nourishment would cost about US$ 65-220 billion (not discounted) during the 21st century and would reduce land loss by 8-14%, forced migration by 56-68% and the cost of forced migration by 77-84% (not discounted). The global share of erodible coast that is nourished increases from about 4% in 2000 to 18-33% in 2100, with beach nourishment being 3-4 times more frequent than shore nourishment, reflecting the importance of tourism benefits. In absolute terms, with or without nourishment, large counties with long shorelines appear to have the largest costs, but in relative terms, small island states appear most impacted by erosion. Considerable uncertainty remains due to the limited availability of basic coastal geomorphological data and models on a global scale. Future work should also further explore the effects of beach tourism, including considering sub-national distributions of beach tourists.
  •  
9.
  • Hinkel, Jochen, et al. (författare)
  • The effects of adaptation and mitigation on coastal flood impacts during the 21st century. An application of the DIVA and IMAGE models
  • 2013
  • Ingår i: Climatic Change. - : Springer Verlag (Germany). - 0165-0009 .- 1573-1480. ; 117:4, s. 783-794
  • Tidskriftsartikel (refereegranskat)abstract
    • This paper studies the effects of mitigation and adaptation on coastal flood impacts. We focus on a scenario that stabilizes concentrations at 450 ppm-CO2-eq leading to 42 cm of global mean sea-level rise in 1995-2100 (GMSLR) and an unmitigated one leading to 63 cm of GMSLR. We also consider sensitivity scenarios reflecting increased tropical cyclone activity and a GMSLR of 126 cm. The only adaptation considered is upgrading and maintaining dikes. Under the unmitigated scenario and without adaptation, the number of people flooded reaches 168 million per year in 2100. Mitigation reduces this number by factor 1.4, adaptation by factor 461 and both options together by factor 540. The global annual flood cost (including dike upgrade cost, maintenance cost and residual damage cost) reaches US$ 210 billion per year in 2100 under the unmitigated scenario without adaptation. Mitigation reduces this number by factor 1.3, adaptation by factor 5.2 and both options together by factor 7.8. When assuming adaptation, the global annual flood cost relative to GDP falls throughout the century from about 0.06 % to 0.01-0.03 % under all scenarios including the sensitivity ones. From this perspective, adaptation to coastal flood impacts is meaningful to be widely applied irrespective of the level of mitigation. From the perspective of a some less-wealthy and small island countries, however, annual flood cost can amount to several percent of national GDP and mitigation can lower these costs significantly. We conclude that adaptation and mitigation are complimentary policies in coastal areas.
  •  
10.
  • Salahuddin, Taufiq, et al. (författare)
  • Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial
  • 2020
  • Ingår i: American Heart Journal. - : MOSBY-ELSEVIER. - 0002-8703 .- 1097-6744. ; 221, s. 60-66
  • Tidskriftsartikel (refereegranskat)abstract
    • Background High-density lipoprotein cholesterol (HDL-C) concentration is inversely related to risk of major adverse cardiovascular events (MACE) in epidemiologic studies but is a poorer predictor of MACE in patients with established coronary heart disease. HDL particle concentration (HDLP) has been proposed as a better predictor of risk. We investigated whether HDLP is associated with risk of MACE after acute coronary syndrome (ACS). Methods The dal-Outcomes trial compared the CETP inhibitor dalcetrapib with placebo in patients with recent ACS. In a nested case-cohort analysis, total, large, medium, and small HDLPs were measured by nuclear magnetic resonance spectroscopy at baseline (4-12 weeks after ACS) in 476 cases with MACE and 902 controls. Hazard ratios (HRs; case-control) for 1-SD increment of HDLP or HDL-C at baseline were calculated with and without adjustment for demographic, clinical, laboratory, and treatment variables. Similarly, HRs for MACE were calculated for changes in HDLP or HDL-C from baseline to month 3 of assigned treatment. Results Over median follow-up of 28 months, the risk of MACE was not associated with baseline HDLP (adjusted HR = 0.98, 95% CI = 0.84-1.15, P =.81), any HDLP subclass, or HDL-C. Dalcetrapib increased HDL-C and total, medium, and large HDLP and decreased small HDLP but had no effect on MACE compared with placebo. There were no association of risk of MACE with change in HDLP or HDL-C and no interaction with assigned study treatment. Conclusions Neither baseline HDLP nor the change in HDLP on treatment with dalcetrapib or placebo was associated with risk of MACE after ACS.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 17
Typ av publikation
tidskriftsartikel (15)
konferensbidrag (2)
Typ av innehåll
refereegranskat (16)
övrigt vetenskapligt/konstnärligt (1)
Författare/redaktör
Leiter, Lawrence A (5)
McMurray, John J. V. (4)
Sun, J. F. (1)
Klein, Richard J T (1)
Tompkins, Emma L. (1)
Sundström, Johan, Pr ... (1)
visa fler...
Agirre, Jon (1)
Atanasova, Mihaela (1)
Bagdonas, Haroldas (1)
Ballard, Charles B. (1)
Basle, Arnaud (1)
Beilsten-Edmands, Ja ... (1)
Borges, Rafael J. (1)
Brown, David G. (1)
Burgos-Marmol, J. Ja ... (1)
Berrisford, John M. (1)
Bond, Paul S. (1)
Caballero, Iracema (1)
Catapano, Lucrezia (1)
Chojnowski, Grzegorz (1)
Cook, Atlanta G. (1)
Cowtan, Kevin D. (1)
Croll, Tristan I. (1)
Debreczeni, Judit E. (1)
Devenish, Nicholas E ... (1)
Dodson, Eleanor J. (1)
Drevon, Tarik R. (1)
Emsley, Paul (1)
Evans, Gwyndaf (1)
Evans, Phil R. (1)
Fando, Maria (1)
Foadi, James (1)
Fuentes-Montero, Lui ... (1)
Garman, Elspeth F. (1)
Gerstel, Markus (1)
Gildea, Richard J. (1)
Hatti, Kaushik (1)
Hekkelman, Maarten L ... (1)
Heuser, Philipp (1)
Hoh, Soon Wen (1)
Hough, Michael A. (1)
Jenkins, Huw T. (1)
Jimenez, Elisabet (1)
Joosten, Robbie P. (1)
Keegan, Ronan M. (1)
Keep, Nicholas (1)
Krissinel, Eugene B. (1)
Kolenko, Petr (1)
Kovalevskiy, Oleg (1)
Lamzin, Victor S. (1)
visa färre...
Lärosäte
Karolinska Institutet (3)
Uppsala universitet (1)
Stockholms universitet (1)
Lunds universitet (1)
Språk
Engelska (17)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (5)
Naturvetenskap (3)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy